Publicacións (55) Publicacións de Luis Ángel León Mateos

2024

  1. Identification of a Proteomic Signature for Predicting Immunotherapy Response in Patients With Metastatic Non-Small Cell Lung Cancer

    Molecular and Cellular Proteomics, Vol. 23, Núm. 10

2023

  1. Extracellular Vesicles’ Genetic Cargo as Noninvasive Biomarkers in Cancer: A Pilot Study Using ExoGAG Technology

    Biomedicines, Vol. 11, Núm. 2

2022

  1. Plasma cell-free DNA and circulating tumor cells as prognostic biomarkers in small cell lung cancer patients

    Translational Lung Cancer Research, Vol. 11, Núm. 10, pp. 1995-2009

2019

  1. Lung Cancer and Liquid Biopsy: Realities and Challenges in Routine Clinical Practice

    Archivos de Bronconeumologia

  2. Lung Cancer and Liquid Biopsy: Realities and Challenges in Routine Clinical Practice

    Archivos de Bronconeumologia, Vol. 55, Núm. 6, pp. 289-290

2018

  1. Enfermedades reumáticas en la adolescencia. Artritis idiopática juvenil. Conectivopatías

    Medicine: Programa de Formación Médica Continuada Acreditado, Serie 12, Núm. 61, pp. 3588-3600

  2. PrediCTC, liquid biopsy in precision oncology: a technology transfer experience in the Spanish health system

    Clinical and Translational Oncology, Vol. 20, Núm. 5, pp. 630-638

  3. Radium-223 international early access program: Results from the Spanish subset

    Future Oncology, Vol. 14, Núm. 1, pp. 41-50

2017

  1. A Prospective Observational Study for Assessment and Outcome Association of Circulating Endothelial Cells in Clear Cell Renal Cell Carcinoma Patients Who Show Initial Benefit from First-line Treatment. The CIRCLES (CIRCuLating Endothelial cellS) Study (SOGUG-CEC-2011-01)

    European Urology Focus, Vol. 3, Núm. 4-5, pp. 430-436

  2. Development of de novo psoriasis during nivolumab therapy for metastatic renal cell carcinoma: immunohistochemical analyses and clinical outcome

    APMIS

  3. Novel potential predictive markers of sunitinib outcomes in long-term responders versus primary refractory patients with metastatic clear-cell renal cell carcinoma

    Oncotarget, Vol. 8, Núm. 18, pp. 30410-30421

2016

  1. Impact on clinical practice of the implementation of guidelines for the toxicity management of targeted therapies in kidney cancer. The protect-2 study

    BMC Cancer, Vol. 16, Núm. 1

2015

  1. New advances in genitourinary cancer: evidence gathered in 2014

    Cancer and Metastasis Reviews, Vol. 34, Núm. 3, pp. 443-464

  2. Side effects of targeted therapy

    Springer New York, pp. 377-416

  3. Treatment Of Sunitinib-Induced Hypertension In Solid Tumors By Nitric Oxid Donors

    Redox biology, Vol. 5, pp. 422

  4. Treatment of sunitinib-induced hypertension in solid tumor by nitric oxide donors

    Redox Biology, Vol. 6, pp. 421-425

  5. Updated recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with metastatic castration-resistant prostate cancer

    Critical Reviews in Oncology/Hematology, Vol. 96, Núm. 2, pp. 308-318

2014

  1. Erratum to: Recommendations for the clinical and radiological evaluation of response to treatment in metastatic renal cell cancer (Targeted Oncology (2014) 9, (9-24) DOI: 10.1007/s11523-013-0304-7)

    Targeted Oncology

  2. Metastatic castration-resistant prostate cancer: Changing landscape with cabazitaxel

    Anti-Cancer Drugs, Vol. 25, Núm. 3, pp. 237-243

  3. Recommendations for the clinical and radiological evaluation of response to treatment in metastatic renal cell cancer

    Targeted Oncology, Vol. 9, Núm. 1, pp. 9-24